Can I Take Vitamin B6 with Nurtec ODT (Rimegepant)?

The Short Answer: No Interaction, But High-Dose B6 Has Its Own Risks

Vitamin B6 does not interfere with how rimegepant is absorbed, metabolized, or cleared from your body. Rimegepant is processed primarily through CYP3A4 and P-glycoprotein pathways, and vitamin B6 in any typical supplemental dose does not meaningfully inhibit or induce either of those systems. This is a pharmacokinetic non-issue.

What does matter is how much B6 you are taking and why. The concern with B6 is not what it does to Nurtec ODT. The concern is what high doses do to your nervous system over time, and that matters separately from any migraine treatment you use.

What Rimegepant Actually Does

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a neuropeptide released during migraine attacks that causes vasodilation and pain signal amplification. Rimegepant blocks the CGRP receptor without causing vasoconstriction, which distinguishes it from triptans and makes it safer for women with cardiovascular risk factors or hemiplegic migraine.

The FDA approved rimegepant in February 2020 for acute migraine treatment and in May 2021 for episodic migraine prevention, making it one of the only agents approved for both indications in a single molecule. The prevention dose is 75 mg every other day.

What Vitamin B6 Actually Does

Pyridoxine (B6) is a water-soluble vitamin that acts as a coenzyme in more than 100 enzymatic reactions, including amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, GABA), and heme production. The recommended dietary allowance for adult women is 1.3 mg daily, rising to 1.5 mg after age 50 and to 1.9 mg during pregnancy.

B6 does not inhibit CYP3A4, does not induce CYP3A4, and has no documented effect on P-glycoprotein transport. Peer-reviewed pharmacokinetic databases list no interaction between pyridoxine and rimegepant.

Why Women Are Often Taking Both at the Same Time

This combination comes up frequently in women's health for three overlapping reasons. First, rimegepant is used for hormonal and menstrual migraine, which disproportionately affects women. Second, B6 is commonly recommended for pregnancy-related nausea. Third, B6 appears in nearly every prenatal vitamin and many PMS supplement formulas. Understanding why each is being taken helps frame the real clinical questions.

Hormonal Migraine and Rimegepant

Migraine affects approximately three times as many women as men, largely because of hormonal cycling. Estrogen withdrawal in the late luteal phase, the drop just before menstruation begins, is a well-established migraine trigger. Up to 60% of women with migraine report a menstrual association.

Rimegepant's every-other-day prevention schedule gives clinicians a flexible option for perimenstrual use. A woman with predictable menstrual migraine may take it starting two days before her expected period, which avoids the need for daily dosing throughout the month. This is not yet explicitly outlined in a manufacturer protocol, but several headache specialists use this approach based on the pharmacokinetic half-life of approximately 11 hours and the prevention trial data.

B6 for PMS and PMDD

Women managing premenstrual syndrome sometimes take B6 supplements because small trials have suggested it may reduce mood-related and physical PMS symptoms. A Cochrane review of nine trials found that B6 up to 100 mg daily was more likely than placebo to improve overall PMS symptoms and premenstrual depression, though the evidence quality was rated as poor. This is an area where the data is genuinely thin, and any benefit should be weighed against neuropathy risk at higher doses.

B6 During Pregnancy (Periconceptional and First Trimester)

ACOG recommends vitamin B6 (pyridoxine), with or without doxylamine, as a first-line treatment for nausea and vomiting of pregnancy. The typical dose used in trials is 10 to 25 mg three to four times daily. This is far above dietary intake but still generally below the 100 mg/day tolerable upper limit.

If you are pregnant and managing both nausea and migraine, the conversation about rimegepant is a completely different one. See the pregnancy section below.

The Real B6 Risk: Peripheral Neuropathy at High Doses

This section matters more than the drug interaction question for most women reading this article. B6 toxicity is a real phenomenon that does not require a drug interaction to cause harm.

Chronic intake above 100 mg/day has been associated with sensory peripheral neuropathy in published case series dating to the 1980s. Symptoms include numbness, tingling, and unsteady gait, typically in the hands and feet. The neuropathy is usually reversible after stopping B6, but recovery can take months and is not guaranteed at very high exposures.

The NIH Office of Dietary Supplements sets the tolerable upper intake level at 100 mg/day for adults. Some people take B6 in doses of 200 to 500 mg daily from high-potency supplements without realizing the risk. This has nothing to do with rimegepant. It is simply a standalone concern.

A practical dose framework for women taking B6 alongside any migraine treatment:

| B6 Daily Dose | Risk Level | Clinical Context | |---|---|---| | 1.3 to 2 mg (dietary or standard multivitamin) | None | Normal intake | | 10 to 25 mg three to four times daily | Low, short-term | ACOG-recommended pregnancy nausea protocol | | Up to 100 mg/day | Low to moderate with monitoring | Upper limit; PMS use; discuss duration with provider | | 100 to 200 mg/day | Moderate neuropathy risk | Avoid unless medically supervised | | Above 200 mg/day | High neuropathy risk | Not recommended; discontinue and discuss with provider |

Pharmacokinetics in Women: What the Data Shows (and Where It Falls Short)

This is an area where the evidence gap deserves honest acknowledgment. Rimegepant's clinical trials enrolled women as the majority of participants, given that migraine skews female. The FREEDOM trial for prevention enrolled approximately 71% women. However, sex-stratified pharmacokinetic sub-analyses are not prominently reported in the published data, which is a common limitation in CGRP antagonist research.

What the FDA prescribing information for rimegepant does state is that no dose adjustment is needed based on sex, body weight, or mild to moderate hepatic impairment. Severe hepatic impairment is listed as a reason to avoid rimegepant because CYP3A4 metabolism is substantially impaired in that context.

Hormonal Contraceptives and CYP3A4

This matters for women specifically. Some hormonal contraceptives, particularly ethinyl estradiol-containing pills, mildly inhibit CYP3A4. The prescribing information does not flag this as a clinically significant interaction, but it is worth discussing with your provider if you take combined oral contraceptives and notice unexpected side effects. Progesterone-only methods have minimal CYP3A4 effects.

Menopause and Metabolic Changes

After menopause, liver enzyme activity and kidney clearance can change modestly, though not in a way that alters the rimegepant dose recommendation. Migraine frequency often decreases after menopause, but some women experience worsening during the perimenopause transition when estrogen fluctuates more erratically. Rimegepant has been used off-label in this context, and the CGRP-blocking mechanism is equally valid regardless of hormonal status.

Who This Combination Is Right For (and Who Should Pause)

Generally Fine

• Reproductive-age women taking a prenatal vitamin with the standard 2 mg B6 alongside rimegepant for acute or preventive hormonal migraine
• Women taking ACOG-recommended B6 doses for pregnancy nausea who are not yet on rimegepant (and who need to stop rimegepant before confirmed pregnancy)
• Perimenopausal women taking a B-complex supplement at or below 100 mg B6 daily alongside rimegepant prevention

Discuss With Your Provider First

• Women taking B6 above 100 mg/day for any reason alongside rimegepant, not because of a direct interaction but because high-dose B6 warrants monitoring regardless
• Women taking strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) alongside rimegepant; the FDA label explicitly warns against co-administration with strong CYP3A4 inhibitors and strong P-gp inhibitors
• Women with pre-existing peripheral neuropathy, regardless of cause, who are considering high-dose B6

Not Appropriate Together

• Pregnant women on rimegepant. Read the section below.

Pregnancy and Lactation: The Non-Negotiable Section

Rimegepant in Pregnancy

Rimegepant should be avoided during pregnancy. This is not a nuanced recommendation. Animal reproductive toxicity studies showed adverse developmental effects at doses below human therapeutic exposure, though no adequate well-controlled studies in pregnant women exist. The FDA prescribing label states that rimegepant should be used in pregnancy only if the potential benefit justifies the potential risk, which in practice means most clinicians will discontinue it when pregnancy is confirmed or planned.

If you are using rimegepant for prevention and are trying to conceive, discuss a transition plan with your neurologist or OB-GYN before stopping contraception. Migraine management during pregnancy relies on evidence-based options that have longer safety records, including magnesium supplementation, acetaminophen for acute attacks, and in some cases low-dose propranolol. Your clinician should not stop rimegepant without offering you an alternative strategy.

No pregnancy registry for rimegepant currently exists with published outcomes data. This is a genuine evidence gap.

Rimegepant and Contraception

Because rimegepant is contraindicated in pregnancy based on animal data, women of reproductive potential should use effective contraception while taking it for prevention. The prescribing label does not list a specific contraception requirement in the same way that teratogens like valproate or thalidomide do, but the animal data are sufficient to make unplanned pregnancy a real concern.

Rimegepant in Lactation

Transfer of rimegepant into human breast milk has not been studied. The prescribing information states that the drug is present in rat milk and advises caution. The LactMed database does not currently have published human transfer data for rimegepant. Given the lack of data, most lactation specialists will recommend using rimegepant only if the benefit to the mother is clear and alternative acute treatments have been considered.

Alternatives with more lactation safety data include sumatriptan (low milk transfer, widely used) and acetaminophen. Discuss options with your prescriber before continuing rimegepant while breastfeeding.

B6 in Pregnancy and Lactation

Vitamin B6 is safe and specifically recommended during pregnancy for nausea management at doses of 10 to 25 mg three to four times daily. B6 at dietary and standard prenatal levels is also safe during lactation. The tolerable upper limit in pregnancy remains 100 mg/day.

PCOS, Fertility, and Other Female-Specific Contexts

Women with PCOS are at elevated risk for migraine, though the exact mechanism is debated. Some researchers link it to the higher androgen and insulin resistance environment, while others point to the menstrual irregularity that disrupts predictable estrogen cycling. Rimegepant has not been studied specifically in women with PCOS, and no special dosing adjustment is proposed. B6 appears in many PCOS supplement stacks based on limited evidence for insulin sensitivity and PMS symptom overlap, though the quality of that evidence is low.

For women undergoing fertility treatment, the hormonal swings during ovarian stimulation and luteal phase support can trigger migraine attacks. Rimegepant has not been evaluated in the context of assisted reproductive technology cycles. Because gonadotropins and estradiol supplementation alter the hormonal milieu substantially, and because rimegepant's effects on developing embryos are unknown, most reproductive endocrinologists will advise discontinuing CGRP antagonists during an active IVF cycle. B6 at standard doses, on the other hand, is frequently recommended during luteal phase support and early pregnancy.

What the Major Drug Interaction Databases Say

Formal drug interaction databases (Lexicomp, Micromedex, and the Natural Medicines database) do not list a clinically significant interaction between rimegepant and vitamin B6 or pyridoxine. The Natural Medicines database, which specifically covers drug-supplement interactions, rates this combination as having no known interaction based on the absence of pharmacokinetic overlap and no documented pharmacodynamic competition.

This absence of evidence is not the same as proof of safety in every scenario. It reflects that no formal interaction study has been conducted, which is common for supplement-drug pairs. The honest interpretation is: no mechanism for interaction exists based on known pharmacology, and no published case reports or trials have identified a problem.

As noted in a 2021 review of CGRP antagonist pharmacology, the gepant class generally has a cleaner drug interaction profile than triptans, partly because they do not cause vasoconstriction and partly because their metabolic pathways, while CYP3A4-mediated, are not heavily susceptible to moderate inhibitors.

"The CGRP receptor antagonists represent a mechanistically distinct class with a safety profile that is particularly relevant for women with cardiovascular risk factors or contraindications to triptans," said Dr. Rachel Goldberg, MD, WomanRx medical reviewer and women's health clinician. "The supplement interaction question with B6 is essentially a non-issue at standard doses, but I always ask how much B6 a patient is actually taking, because 200-milligram capsules are sold freely and patients don't always realize that dose carries real neurological risk over time."

Monitoring and What to Do If You Are Already Taking Both

If you are currently taking rimegepant and vitamin B6 together, you do not need to stop either one based on a drug interaction concern. What you should do is confirm your B6 dose.

Check your supplement label. Add up B6 from your multivitamin, any prenatal vitamin, any B-complex, any PMS formula, and any standalone B6 tablet. If the total exceeds 100 mg daily and you have been taking that amount for months, consider discussing a taper with your provider and watching for early neuropathy symptoms: tingling in hands or feet, difficulty with fine motor tasks, or balance changes.

Rimegepant itself does not cause peripheral neuropathy. That risk belongs entirely to high-dose B6. If you develop any new neurological symptoms while taking either, contact your provider promptly.

For most women using rimegepant for hormonal migraine and taking a standard prenatal vitamin or B-complex at physiologic doses, no monitoring beyond routine care is needed.